ClinicalTrials.gg
RecruitingNCT07691749Updated Sep 30, 2026

Effect of Psychobiotics With Standard Antiddepressants in Treatment of Major Depressive Disorder

An interventional study of Lactobacillus Helveticus and bifidobacterium Longum and Placebo Capsule(s) in Major Depression, sponsored by Dr Sadia yasir. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Dr Sadia yasir · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2026, registered Jul 2026).
  • Started Jan 2026; still recruiting 9 months later.
Updated Sep 30, 2026Study documents postedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Depressive Disorder, Major with a site in Pakistan — 7 open to participants now, 7 under way, 1 of them phase 3. Depressive Disorder, Major · Pakistan.

Planned enrollment
8th of 17
86 · median 80
Started
2026
with 3 others
No phase
13 of 18
6 open now
Registered
15th of 18
by date
Lead sponsor
1 of 18
Dr Sadia yasir

Among the 18 studies in Depressive Disorder, Major with a site in Pakistan, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2026, is one of 13 with no phase, and was the 15th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 18 studies in Depressive Disorder, Major with a site in Pakistan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Depressive Disorder, Major with a site in Pakistan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether adding psychobiotics (a combination of Lactobacillus helveticus and Bifidobacterium longum) to standard antidepressant treatment works better than antidepressants alone for adults with major depressive disorder. The study will also learn about the safety of taking these psychobiotics with antidepressants.

The main questions it aims to answer are:

  1. Does adding psychobiotics lower depression symptoms more than a placebo (a look-alike capsule with no active ingredients)?
  2. Is it safe and well tolerated when taken with standard antidepressant treatment?

Researchers will compare psychobiotic capsules with placebo capsules to see whether psychobiotics improve depression symptoms when used together with standard antidepressants.

Participants will:

  1. Continue taking their prescribed antidepressant medicine. Be randomly assigned to receive either a psychobiotic capsule or a placebo capsule once daily for 6 weeks.
  2. Complete depression assessments at the start of the study and again at 3 and 6 weeks.
  3. Attend regular follow-up visits so researchers can monitor symptoms, side effects, and overall progress
Read the detailed description

Major depressive disorder (MDD) is a leading cause of disability worldwide, and many patients experience only partial improvement with antidepressant treatment alone. Increasing evidence suggests that the gut-brain axis plays an important role in the pathophysiology of depression. Psychobiotics, including Lactobacillus helveticus and Bifidobacterium longum, may improve depressive symptoms by modulating the gut microbiota, reducing inflammation, and influencing neurochemical pathways.

This study is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of adjunctive psychobiotic therapy in adults with MDD receiving standard antidepressant treatment. Participants will continue their prescribed antidepressant medication and will be randomly assigned to receive either a psychobiotic capsule containing Lactobacillus helveticus and Bifidobacterium longum or a matching placebo once daily for 6 weeks.

Depression severity will be assessed at baseline, Week 3, and Week 6 using validated rating scales. Safety and tolerability will be evaluated through adverse event monitoring, treatment adherence, and regular follow-up visits.

The primary objective is to determine whether adjunctive psychobiotic therapy produces a greater reduction in depressive symptoms compared with placebo. Secondary objectives include evaluating safety, tolerability, treatment adherence, patient satisfaction, and quality of life. The findings will provide evidence on whether psychobiotics are an effective and safe adjunct to antidepressant therapy in adults with major depressive disorder.

03

Conditions studied

  • Major Depression

Keywords

  • Psychobiotics
  • Major Depressive Disorder
  • Lactobacillus Helveticus
  • Bifidobacterium longum
  • Gut-Brain Axis
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Adjunctive Therapy
  • Placebo-Controlled Trial
  • Hamilton Depression Rating Scale (HDRS-17)
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with major depressive disorder (According to Diagnostic \& Statistical Manual-5 criteria (as per operational definition)
  2. Age 18 to 60 years
  3. Both genders
  4. Patients who are able to speak and understand Urdu/ English language.
  5. Patients who are on stable doses of oral selective serotonin reuptake inhibitors for at least two weeks prior to enrollment in the study
  6. Patients with cut off score of > 24 as assessed by 17 item clinician administered Hamilton depression rating scale.

Exclusion criteria

Exclusion Criteria:

  • Severe psychiatric comorbidities (schizophrenia, bipolar disorder, co morbid substance use)

    • Individuals with weakened immune systems: This includes patients undergoing chemotherapy, transplant recipients, and people with conditions like /AIDS.
    • Individuals on chronic medication: People on chronic pharmacological therapy, especially with anti-inflammatory drugs or who have recently used antibiotics in last 2 weeks.
    • Pregnant or lactating women
    • Current use of probiotics or prebiotics
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Active comparator
    Interventional Arm

    People who are recieving Psychobiotics as an adjunct to the standard treatment.

    Dietary Supplement: Lactobacillus Helveticus and bifidobacterium Longum

  • Placebo comparator
    Placebo Comparator

    people who will be given placebo capsules along with standard treatment

    Other: Placebo Capsule(s)

Interventions

  • Dietary supplementLactobacillus Helveticus and bifidobacterium Longum

    Drug pages: Lactobacillus helveticus · Bifidobacterium longum

    This study uses a specific combination of two well-studied psychobiotic strains-Lactobacillus helveticus R0052 (1.8 billion CFU) and Bifidobacterium longum R0175 (1.2 billion CFU). These strains have been selected because they may support communication between the gut and the brain and help improve mood when used alongside standard antidepressant treatment.

    Also known as: psychobiotics

  • OtherPlacebo Capsule(s)

    A placebo capsule is an orally administered capsule formulated with inert gelatin and no active ingredients. It has no psychobiotic potential and is pharmacologically inactive. The capsule is not expected to affect study outcomes or interact with oral selective serotonin reuptake inhibitors (SSRIs)

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Depression Rating Scale-17 (HDRS-17) Total Score

    The primary outcome is the difference in the mean change in the 17-item Hamilton Depression Rating Scale (HDRS-17) total score from baseline to Week 6 between participants receiving psychobiotics (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) plus standard antidepressant treatment and those receiving placebo plus standard antidepressant treatment. Higher reductions in HDRS-17 scores indicate greater improvement in depressive symptoms.

    Time frame: Baseline to Week 6

07

Study locations

1 of 1 sites recruiting
  • Allama Iqbal Medical College, Jinnah Hospital Lahore
    Lahore, Punjab Province 54550, Pakistan
    Recruiting
    • Head Of Department, PSYCHIATRY DEPARTMENT · Contactpsychjhl@aimc.edu.pk · +923334746639
    • AROOJ FATIMA, MBBS, MD PSY · Sub investigator
    • ZAINAB MAHMOOD, MBBS, FCPS · Sub investigator
    • TEHREEM KHAN, MBBS · Sub investigator
    • TARIQ ABBAS, MBBS · Sub investigator
    • MOHSIN ALI, MBBS · Sub investigator
    • TAYYAB RAFIQUE, MBBS · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 651 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 10 months is below that.

Counting every sponsor, half of 691 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 9, 2026
StartActual
Jan 31, 2026
Primary completionEst.
Dec 25, 2026
CompletionEst.
Jan 31, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: a•••@yahoo.com · •••7690→a•••@yahoo.com · •••7690; added a•••@yahoo.com · •••7690. See the current contact
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Contact Study contact changed: a•••@yahoo.com · •••7690→a•••@yahoo.com · •••7690; added a•••@yahoo.com · •••7690. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07691749
Lead sponsor
Dr Sadia yasir
Collaborators
Allama Iqbal Medical College, Jinnah Hospital
Responsible party
Dr Sadia yasir (Associate Professor/ Head of Department, Jinnah Hospital) — Sponsor-investigator
First posted
Jul 9, 2026
Start date
Jan 31, 2026
Primary completion
Dec 25, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Arooj Fatima Senior Registrar, Psychiatry Department, MBBS, MD Psychiatry
Contact
aroojfatima47@yahoo.com
+923314567690
Arooj Fatima, MBBS, MD Psychiatry
Contact
aroojfatima47@yahoo.com
+923314567690
Sadia Yasir, MBBS FCPS
study chair · Jinnah hospital lahore/ Allama Iqbal Medical college lahore, Pakistan
Arooj Fatima
principal investigator · Jinnah Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lactobacillus helveticus · Bifidobacterium longum

Start the discussion